Kyverna Therapeutics Announces Leadership Update
Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...
Multiple Myeloma Research Foundation Raises More Than $110,000 During 250-Mile Fundraising Ride In CA Wine Country
NORWALK, CT, UNITED STATES, September 18, 2024 /EINPresswire / -- Multiple Myeloma Research Foundation (MMRF) Raises More than $110,000 During 250-Mile Fundraising Ride in California's Wine Country.
CEO exits from company with 2nd-largest biotech IPO this year
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
FierceBiotech1d
Chutes & Ladders—2 Kite vets fly over to Kyverna Therapeutics
Warren Biddle hit the exit from his role as SVP, global head of commercial at Gilead’s CAR-T unit Kite Pharma to take on the ...
Nasdaq4d
2 Breakout Biotech Stocks With CEO Insider Buying
The biotech has been the subject of heavy insider buying this month, including by CEO Sergio Traversa, who purchased roughly $395,000 worth of shares at $2.82 each on Sept. 11. That marked the CEO ...
Business Insider5d
The 80-year-old billionaire Larry Ellison wins plaudits for looking 30 years younger, with the longevity fanatic Bryan Johnson weighing in
The antiaging advocate Bryan ... Johnson chimed in. "Ellison, now 80, is doing a good job managing biological aging," Johnson, the founder of the payments company Braintree, wrote on X. The ...
Yahoo Finance4d
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
suggesting the potential multiple roles of CM24 in overcoming immune evasion,” stated Purple Biotech CEO Gil Efron. “Moreover, these data enable us to potentially design biomarker- guided ...
Technical3d
The biotech startup helping prepare pharma for a ‘post-AI world’
BioPhy was founded by a Wharton grad and former Johnson & Johnson engineer, the latest guest on the Founding Philly podcast.
Stockhouse3d
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
stated Purple Biotech CEO Gil Efron. “Moreover, these data enable us to potentially design biomarker- guided studies for CM24 for the treatment of pancreatic ductal adenocarcinoma (PDAC), as well as ...